News and Events

Comprehensive analysis of baseline variables that predict the benefit of pembrolizumab monotherapy for advanced melanoma patients

15 January 2021

This recent study serves as a comprehensive analysis of baseline variables that predict the benefit of pembrolizumab monotherapy. It concludes that multiple baseline variables correlate with survival on pembrolizumab. Total metabolic tumor volume (TMTV) is a more comprehensive baseline biomarker than C-reactive protein (CRP), lactate dehydrogenase (LDH), or absolute lymphocyte count (ALC) in predicting the futility of pembrolizumab.

Skin penetration enhancement strategies used in the development of melanoma topical treatments

15 January 2021

Currently, research groups are trying to circumvent the stratum corneum barrier, which limits the penetration of drugs through the skin, by using skin penetration enhancement (SPE) strategies. The SPE strategies investigated include chemical skin penetration enhancers (CPEs), physical skin penetration enhancers (PPEs), nanocarrier systems, and a combination of SPE strategies (cream). Of these, PPEs and cream are the most advanced approaches in terms of preclinical and clinical studies, respectively.

Vemurafenib modifies glycans structures and metallomics profile in melanoma cells harboring BRAF mutation

14 January 2021

According to this recent study, vemurafenib modifies the glycans structures and metallomics profile in melanoma cells harboring BRAF mutation that can be further implied in the resistance phenomenon. It opens a new avenue for further studies in the short-term addressing novel targets that hopefully can be used to improve the therapeutic regiment in advanced melanoma patients. 

Global Burden of Disease Study (​GBD 2017) may help to direct resources and allocate funding to close the gap in global skin cancer disparities

14 January 2021

The incidence, prevalence, and disability-adjusted life years (DALYs) of skin cancers are increasing disproportionately among different demographic groups. As a worldwide epidemiological assessment, the Global Burden of Disease Study (GBD 2017) provides frequently updated measures of the skin cancer burden, which may help to direct resources and allocate funding to close the gap in global skin cancer disparities.

Regular 6- or 12-monthly CT or PET/CT surveillance has reasonable and consistent sensitivity and specificity over 5-year follow-up for resected stage IIIA–D melanoma patients

11 January 2021

According to this recent study, regular 6- or 12-monthly surveillance imaging using CT or PET/CT has reasonable and consistent sensitivity and specificity over 5-year follow-up for resected stage IIIA–D melanoma patients. These data are useful when discussing the risks and benefits of long-term follow-up.